Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System
Incorporating the Oncotype DX test is expected to optimize chemotherapy recommendations, reduce overtreatment, and generate cost savings in most subgroups. In Brazil's private health care system, the reduction in chemotherapy-related costs is anticipated to fully or partially offset the cost of testing.
Authors
- Ivan Ricardo Zimmermann (ORCID: https://orcid.org/0000-0001-7757-7519)
- Carlos Magliano
- Carlos Henrique dos Anjos (ORCID: https://orcid.org/0000-0002-2815-0882)
- Júlio Araújo
- Gustavo Miranda Pires Santos
- Daniela Dornelles Rosa (ORCID: https://orcid.org/0000-0002-6196-1919)
- Daniele Xavier Assad (ORCID: https://orcid.org/0000-0001-9722-0904)
- Max S. Mano (ORCID: https://orcid.org/0000-0001-5666-5261)
- Andrea Kazumi Shimada (ORCID: https://orcid.org/0000-0001-7221-3054)
- Tomás Reinert (ORCID: https://orcid.org/0000-0003-4715-1415)
- Leandro Jonata de Carvalho Oliveira (ORCID: https://orcid.org/0000-0001-6344-3544)
- Márcia Gisele Santos da Costa (ORCID: https://orcid.org/0000-0003-3861-5257)
- Sérgio Oliveira
- Steve Millen
- Virginia Areal
Institutions
- Universidade de Brasília (BR)
- Brazilian Development Bank (BR)
- Hospital Israelita Albert Einstein (BR)
- Santa Casa Hospital (BR)
- Hospital Moinhos de Vento (BR)
- Instituto do Câncer do Estado de São Paulo (BR)
- MedSIR (Spain) (ES)
- D’Or Institute for Research and Education (BR)
- Hospital Sírio-Libanês (BR)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1200/go-25-00245
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00